Esperion Therapeutis.Inc. buy Piper Sandler
Start price
25.11.25
/
50%
€3.00
Target price
25.11.26
€7.81
Performance (%)
-37.62%
Price
18:27
€1.87
Summary
This prediction is currently active. The BUY prediction by Piper_Sandler for Esperion Therapeutis.Inc. is performing very badly with a performance of -37.62%. This prediction currently runs until 25.11.26. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | -18.196% | -18.196% |
| iShares Core DAX® | 2.554% | 0.562% |
| iShares Nasdaq 100 | 2.742% | -0.599% |
| iShares Nikkei 225® | 6.584% | 4.336% |
| iShares S&P 500 | 1.930% | -0.507% |
Comments by Piper_Sandler for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat